Orlistat, a reduced form of the natural product lipstatin, is FDA approved as an oral anti-obesity drug since it inhibits gastric/pancreatic lipases and thereby decreases absorption. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.